GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aridis Pharmaceuticals ARDS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$19.3m

FY2015FY2022

Net income

−$30.7m

FY2015FY2022

Free cash flow

−$29.2m

FY2015FY2022

Shareholders' equity

−$24.2m

FY2015FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$19.3m$1.5m$1.0m$1.0m$2.8m$860,000$2.3m$2.9m
Research and development$25.9m$37.9m$17.0m$24.1m$23.0m$17.4m$6.3m—
Operating income−$30.0m−$43.7m−$22.4m−$29.1m−$24.1m−$19.7m−$7.9m−$7.9m
Net income−$30.7m−$42.3m−$22.3m−$29.0m−$22.1m−$24.7m−$8.4m−$8.2m
Diluted earnings per share-1.14-2.92-2.26-3.25-2.73-3.12-0.23-0.22

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$14.7m$26.8m$15.1m$28.0m$31.6m$26.5m$22.5m$3.9m
Cash and short-term investments$4.9m$20.0m$8.2m$20.9m$24.2m$25.1m$22.3m$2.9m
Total liabilities$38.9m$40.9m$23.8m$24.3m$5.3m$15.0m$8.8m$5.9m
Debt$6.1m$6.0m$715,000—$2.5m——$3.7m
Shareholders' equity−$24.2m−$13.1m−$8.7m$3.6m$26.3m$11.4m$13.8m−$2.0m
Shares outstanding27m14m10m9m8m8m37m37m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$29.1m−$22.9m−$20.5m−$8.2m−$24.3m−$17.6m−$6.1m−$4.5m
Capital spending−$82,000−$530,000−$367,000−$174,000−$677,000−$698,000−$15,000−$1,000
Free cash flow−$29.2m−$23.5m−$20.8m−$8.3m−$24.9m−$18.3m−$6.1m−$4.5m
Dividends paid—−$4.1m——−$1.4m———

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Revenue$417,000$19.6m———$292,000$570,000$570,000
Operating income−$869,000$13.7m−$6.3m−$7.4m−$7.4m−$7.7m−$7.4m−$10.0m
Net income−$83,000$12.1m−$6.8m−$6.4m−$9.1m−$8.2m−$8.1m−$10.2m
Diluted earnings per share-0.000.32-0.18-0.24-0.34-0.30-0.30-0.71
Cash from operations—−$4.0m−$4.0m−$4.0m−$4.0m−$6.0m−$10.0m−$3.0m
Total assets$6.5m$6.5m$9.4m$14.7m$12.1m$16.7m$23.8m$26.8m
Cash and short-term investments$35,000$19,000$1.3m—$1.9m$6.3m$12.5m$20.0m
Debt$4.0m$5.3m$2.8m—$12.7m$11.4m$11.3m$5.3m
Shareholders' equity−$11.8m−$14.9m−$27.9m−$24.2m−$35.8m−$27.9m−$20.4m−$14.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue166.1%86.2%—
Operating income1.0%8.7%—
Net income2.0%4.5%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-354.6%-548.9%-639.7%—
Net margin-351.4%-545.2%-647.6%—

Share price return

Finished calendar years

20252024202320222021202020192018
Return2613573%-99%-93%-61%-61%54%-48%-38%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.